Ascendis Pharma 2025-26: Yorvipath €477M, OCF €500M FY26 Target

FY25 revenue $692M (+90% YoY) reflecting Yorvipath + Skytrofa commercial ramp; op income -$131M (vs -$279M FY24, narrowing losses); NI -$219M (vs -$378M FY24); EPS -$3.62 (vs -$6.53). FCF $44M (positive, vs -$308M FY24 — major inflection). Yorvipath: Q4 2025 revenue €187M / full-year 2025 revenue €477M. US: over 5,300 patients prescribed by nearly 2,400 providers; less than 5% of US patients on treatment; insurance approval rate ~70%; majority approvals within 8 weeks. Outside US: available in 30+ countries; full commercial reimbursement in 4 Europe direct and 2 international markets; expect 10 new country launches in 2026. Skytrofa: Q4 2025 revenue €53M / full-year €206M. Market share ~7% in US. Initiated Phase III basket trial for additional growth hormone indications. TransCon CNP: pivotal trial showed significant improvement vs placebo; NDA for children with achondroplasia in US under review; MAA in EU underway; Phase II combination trial data shows dual therapy potential with TransCon Growth Hormone. Partnership with Novo Nordisk for once-monthly TransCon semaglutide. Total debt $871M (+2%). FY26 guide: continued strong Yorvipath growth (steady patient uptake with seasonality); Skytrofa seasonal pattern with revenue tracking prescriptions; aim to achieve operating cash flow of ~€500M in 2026; at least €5B in annual product revenue by 2030; TransCon CNP approval in US excluded from 2026 outlook.

Key takeaways

• Yorvipath FY revenue €477M (Q4 €187M run rate ~€750M annualized) — multi-year hypoparathyroidism inflection. Yorvipath (TransCon PTH for hypoparathyroidism) generated €477M FY25 revenue with Q4 €187M (annualizing to ~€750M+) — the cleanest evidence of a commercial inflection in this multi-year underserved disease market. US: 5,300+ patients prescribed by ~2,400 providers; ~70% insurance approval; <5% of US patients on treatment — meaningful runway given the multi-year market expansion thesis. Outside US: 30+ countries with full commercial reimbursement in 4 EU direct + 2 international; 10 new country launches in 2026.

• TransCon CNP NDA under FDA review for achondroplasia + Phase II combination dual-therapy potential — multi-year pipeline catalyst. TransCon CNP (next-generation drug for achondroplasia) showed significant pivotal trial improvement vs placebo; NDA filed in US for children with achondroplasia and currently under FDA review; MAA filed in EU. Phase II combination trial data showed dual therapy potential with TransCon Growth Hormone — multi-year combination opportunity creates additional revenue layer. TransCon CNP US approval excluded from 2026 outlook = upside optionality for FY26-27.

• Skytrofa €206M FY revenue / 7% US market share — secondary franchise compounding. Skytrofa (long-acting growth hormone for pediatric growth hormone deficiency) generated €206M FY25 revenue with ~7% US market share. Phase III basket trial initiated for additional growth hormone indications — multi-year label expansion opportunity. Combined with seasonal Q4 €53M run-rate, Skytrofa is a multi-year compounder providing diversification beyond Yorvipath.

• FY26 OCF target ~€500M + 2030 revenue target €5B+ — multi-year cash flow inflection + path to scale. Management guided to operating cash flow of ~€500M in 2026 — meaningful inflection from -$308M FCF FY24. Combined with the 2030 target of €5B+ in annual product revenue (vs FY25 ~€680M+), the multi-year scale-up trajectory is meaningful. Yorvipath patient uptake + Skytrofa label expansion + TransCon CNP launch (excluded from FY26 outlook but adding 2026-2027 upside) + multi-year geographic + indication expansion = clear path to €5B 2030 target.

• Novo Nordisk partnership for once-monthly TransCon semaglutide — strategic platform validation. Ascendis partnered with Novo Nordisk on a once-monthly TransCon semaglutide development program. The partnership leverages Ascendis' TransCon prodrug platform technology applied to Novo's GLP-1 franchise — multi-billion dollar TAM optionality given current GLP-1 obesity market dynamics. Partnership economics + multi-year clinical milestones provide additional upside beyond core franchise.

Business

Ascendis Pharma A/S is a Denmark-domiciled biopharmaceutical company with multi-year endocrinology franchise + TransCon prodrug platform technology, multi-product portfolio:

• Yorvipath / TransCon PTH (~70% of revenue, fastest growing): TransCon PTH for hypoparathyroidism. FY25 revenue €477M (Q4 €187M). US 5,300+ patients on treatment.
• Skytrofa / TransCon hGH (~30%): Long-acting growth hormone for pediatric growth hormone deficiency. FY25 revenue €206M. ~7% US market share. Phase III basket trial initiated for additional indications.
• TransCon CNP (Pipeline): Next-generation achondroplasia drug. NDA under FDA review; MAA EU underway. Phase II combination trial dual-therapy potential.
• Novo Nordisk Partnership: TransCon semaglutide once-monthly development program.
• TransCon Prodrug Platform: Multi-year proprietary platform technology for sustained-release biologics.

Strategic moves FY25:

• Yorvipath FY revenue €477M (Q4 €187M ~€750M annualized)
• US: 5,300+ Yorvipath patients; 2,400+ providers; ~70% approval
• Outside US: 30+ countries; 10 new country launches in 2026
• Skytrofa €206M FY; ~7% US market share; Phase III basket trial initiated
• TransCon CNP pivotal trial positive vs placebo; NDA filed US; MAA EU
• TransCon CNP combination trial Phase II data
• Novo Nordisk partnership for once-monthly TransCon semaglutide
• FY25 FCF positive ($44M, vs -$308M FY24)
• Operating loss narrowing ($131M, from $279M FY24)

FY25 financial performance

Note: ASND reports in EUR; FS data shown converted to USD. Q4 call references EUR figures; revenue $692M FY25 USD ≈ €600M+ FY25 EUR (depending on FX). Yorvipath €477M + Skytrofa €206M = €683M product revenue.

The earnings progression: revenue ramped dramatically $51M → $692M (FY22-25, +13.5x over 3 years). Operating losses narrowing each year as commercial scale builds: -$562M (FY22) → -$131M (FY25). FCF turned positive in FY25 ($44M) — first positive FCF year. Multi-year operating leverage thesis intact.

Capital allocation

• Capex: $-8M FY25 (capital-light biopharma model).
• Dividends: $0 (no dividend; growth phase).
• Buybacks: $-17M FY25 (modest).
• Total debt: $871M (+2% YoY).
• FCF: $44M FY25 (positive, vs -$308M FY24) — major inflection.
• FY26 OCF target: €500M ($540M USD).

FY26 outlook (per Q4 2025 call, 2026-02-11)

Management noted continued multi-year transformation into leading global biopharma + Yorvipath label expansion + Skytrofa Phase III + TransCon CNP combination + Novo Nordisk partnership.

Key risks

Yorvipath commercial execution. Multi-year patient adoption + payer approval + provider awareness all matter for the multi-year market expansion thesis.

Hypoparathyroidism market dynamics. Multi-year addressable market of ~80,000 US patients + multi-region expansion + competitive landscape (Crinetics, Amolyt acquired by AstraZeneca, others developing).

TransCon CNP regulatory approval timing. FDA review timing + label dynamics + reimbursement matter for FY26+.

Skytrofa competitive landscape. Long-acting growth hormone competition: NovoNordisk Sogroya, Pfizer Genotropin, Lilly Humatrope, others. Multi-year share dynamics.

Pipeline execution risk. Multi-year clinical trial execution required for label expansions + new indications.

Novo Nordisk partnership economics. Multi-year semaglutide partnership + clinical milestones + commercial economics matter.

FX (EUR/USD). Multi-region operations expose to FX volatility on USD reporting basis.

FDA / EMA regulatory environment. Multi-year regulatory dynamics + label expansion + new approvals.

M&A integration / partnerships. Multi-year partnership pipeline carries execution risk.

Cash burn vs scale. Path to €500M OCF FY26 requires continued commercial inflection.

TransCon platform technology. Multi-year platform technology dynamics + IP + competition from rival prodrug platforms.

Market access / reimbursement. Multi-year payer + reimbursement + IRA pricing dynamics.

Manufacturing scale. Multi-year manufacturing capacity + Yorvipath supply chain.

Insurance approval timeline. Q4 ~70% approval rate + 8-week median; future improvements matter.

International expansion execution. 10 new country launches in 2026 require multi-year execution.

Bottom line

Ascendis Pharma FY25 is the commercial inflection + FCF inflection + pipeline progression year: revenue $692M (+90%); op income -$131M (vs -$279M FY24, narrowing); NI -$219M (vs -$378M FY24); EPS -$3.62; FCF $44M (positive, vs -$308M FY24). Yorvipath FY €477M (Q4 €187M ~€750M annualized); US 5,300+ patients prescribed by ~2,400 providers; <5% US patients on treatment; ~70% insurance approval; 30+ countries; 10 new country launches FY26. Skytrofa FY €206M; ~7% US market share; Phase III basket trial initiated. TransCon CNP pivotal positive; NDA US under review; MAA EU underway; Phase II combination dual-therapy potential. Novo Nordisk partnership for once-monthly TransCon semaglutide. Total debt $871M.

FY26 guide: Yorvipath continued strong growth; Skytrofa seasonal; OCF target ~€500M; 2030 revenue target €5B+; TransCon CNP approval excluded from FY26 outlook (upside).

The risks are real — Yorvipath commercial execution, hypoparathyroidism market dynamics + competition (Crinetics, Amolyt / AstraZeneca), TransCon CNP regulatory approval timing, Skytrofa competitive landscape (Novo Sogroya, Pfizer Genotropin, Lilly Humatrope), pipeline execution risk, Novo Nordisk partnership economics, FX (EUR/USD), FDA / EMA regulatory environment, M&A integration / partnerships, cash burn vs scale, TransCon platform technology dynamics, market access / reimbursement, manufacturing scale, insurance approval timeline, international expansion execution.

But the structural thesis (Denmark-domiciled biopharma + TransCon prodrug platform technology + Yorvipath / TransCon PTH €477M FY25 (US 5,300+ patients <5% market penetration) + Skytrofa €206M / ~7% US market share + Phase III basket trial + TransCon CNP NDA under review + MAA EU + Phase II combination dual-therapy + Novo Nordisk partnership for once-monthly TransCon semaglutide + FY25 FCF positive ($44M) + FY26 OCF target ~€500M + 2030 revenue €5B+ target) is intact and FY25 confirms.

Quality global endocrinology biopharma + TransCon platform compounder mid-commercial-launch, with Yorvipath multi-year inflection + Skytrofa secondary franchise + TransCon CNP pipeline + Novo Nordisk semaglutide partnership + multi-year platform technology + path to €5B 2030. The FY25 +90% revenue + FCF positive inflection + 5,300+ Yorvipath patients + Phase III Skytrofa + NDA TransCon CNP + Novo Nordisk semaglutide + FY26 OCF €500M + 2030 €5B target creates one of the cleaner endocrinology biopharma compounding setups for investors seeking exposure to hypoparathyroidism + achondroplasia + growth hormone + TransCon platform + GLP-1 partnership optionality + multi-year scale-up. The conservative FY26 framework + 10 country launches + Yorvipath US runway + Skytrofa label expansion + TransCon CNP approval upside + Novo Nordisk partnership provides multiple paths to outperformance over a multi-year horizon. Yorvipath commercial + competitive landscape + regulatory approval + pipeline execution + cash burn / scale dynamics remain ongoing risks, but the multi-product diversification + TransCon platform + Novo partnership + Yorvipath inflection + 2030 €5B target support continued multi-year compounding.

Citations

• Ascendis Pharma A/S FY25 Form 20-F (filed February 2026, SEC EDGAR).
• ASND Q4 2025 earnings call, 2026-02-11 — Yorvipath: Q4 2025 revenue €187M; full-year 2025 revenue €477M. US: over 5,300 patients prescribed by ~2,400 providers; less than 5% of US patients on treatment; insurance approval rate ~70%; majority approvals within 8 weeks. Outside US: available in 30+ countries; full commercial reimbursement in 4 Europe direct + 2 international markets; expect 10 new country launches in 2026. Skytrofa: Q4 2025 revenue €53M; full-year €206M. Market share ~7% in US. Initiated Phase III basket trial for additional growth hormone indications. TransCon CNP: pivotal trial showed significant improvement vs placebo; NDA for children with achondroplasia in US under FDA review; MAA in EU underway; Phase II combination trial data shows dual therapy potential with TransCon Growth Hormone. Partnership with Novo Nordisk for once-monthly TransCon semaglutide. FY26 guide: continued strong revenue growth for Yorvipath (steady patient uptake with seasonality); Skytrofa seasonal pattern with revenue tracking prescriptions; aim for operating cash flow of ~€500M in 2026; at least €5B in annual product revenue by 2030; TransCon CNP approval in US later this month excluded from 2026 outlook.
• ASND Q3 / Q2 / Q1 2025 earnings calls — supporting Yorvipath + Skytrofa + TransCon CNP commercial ramp + pipeline progression.
• Internal financial_statements view (consolidated annual + cash flow + capital structure).